# Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

> **NCT04476459** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Huiqiang Huang** · enrollment: 33 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Follicular Lymphoma Grade IIIb
- Transformed Lymphoma
- EBV-Positive DLBCL, Nos
- ALK-Positive Anaplastic Large Cell Lymphoma

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04476459
- **Lead sponsor:** Huiqiang Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-23
- **Primary completion:** 2022-08-01
- **Final completion:** 2023-08-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2021-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476459, "Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04476459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*